Brand:
Dragon Pharma, Europe
Manufacturer:
Dragon Pharma, Europe
Dosage Info:
<div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel">
<section class="tab-panel" id="panel-usage">
<h2>Dosage & Usage Guidelines</h2>
<p>A typical dosing protocol involves administering <strong>500 to 1000 mcg of CJC-1295 DAC</strong> two or three times per week. Since it has a prolonged half-life, frequent daily injections are unnecessary. For best results, it's often taken on an empty stomach in the morning or before sleep. CJC-1295 DAC can be stacked with other peptides like <a href="https://www.dragonpharma.net/peptides-414/ipamorelin-45654">Ipamorelin</a> to amplify GH release or used alone for sustained results.</p>
<h3>Example CJC-1295 DAC Cycle</h3>
<ul>
<li><strong>Weeks 1–12:</strong> 750 mcg CJC-1295 DAC twice weekly</li>
<li><strong>Optional Stack:</strong> Add Ipamorelin 200–300 mcg per injection</li>
<li><strong>Goal:</strong> Body recomposition (fat loss and lean muscle maintenance)</li>
</ul>
<h3>Benefits of CJC-1295 DAC</h3>
<ul>
<li>Improved fat metabolism and reduction of abdominal fat</li>
<li>Faster muscle recovery and repair</li>
<li>Increased IGF-1 levels and protein synthesis</li>
<li>Enhanced sleep and skin elasticity</li>
<li>Minimal injection frequency (2–3x weekly)</li>
</ul>
<h3>Potential Side Effects</h3>
<p>CJC-1295 DAC is generally well tolerated. Mild side effects may include temporary injection site irritation, flushing, or dizziness. These are usually short-lived. To minimize any risks, follow proper reconstitution and administration protocols.</p>
<h3>Do You Need PCT?</h3>
<p>CJC-1295 DAC does not suppress natural testosterone, so traditional post-cycle therapy (PCT) is not required. However, some users transition into lighter peptides or GH boosters to maintain the momentum.</p>
<p>Looking to combine it with other top-tier performance enhancers? Browse our <a href="/">trusted Dragon Pharma store</a> for a complete line of growth peptides, fat burners, and anabolic compounds.</p>
</section>
</div>
Technical Details
Peptide Type
Long-Acting GHRH Analogue
Peptide Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Peptide Length
29 Amino-Acid Residues
Modification
Drug Affinity Complex (DAC)
DAC Attachment Site
Modified Lysine at Position 12
Affinity Mechanism
Covalent Albumin Binding
Receptor Target
GHRH Receptor (GHRHR)
Research Pathway
GHRH / Growth Hormone Axis
Development Status
Investigational